Health
Sobi Receives Health Canada Approval for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced proteinuria, stabilized kidney function and C3 deposit clearance WALTHAM, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that Health Canada has approved EMPAVELI® (pegcetacoplan), a complement inhibitor, for the treatment of adult and
About this update from Swedish Orphan Biovitrum Ab
[{"type":"image","alt":"Sobi, Inc.","displaySize":"","headline":null,"caption":"Sobi, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/860496ad964984ca29b78786bfce3044"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1.dwKuBZkSCEq3LTqTbQ4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNQ--/https://media.zenfs.com/en/globenewswire.com/860496ad964984ca29b78786bfce3044","width":300,"height":82}},"lazy":false},{"type":"text","content":"EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada","length":126,"tagName":"p"},{"type":"text","content":"Approval supported by Phase 3 52-week VALIANT study demonstrated reduced proteinuria, stabilized kidney function and C3 deposit clearance","length":137,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that Health Canada has approved EMPAVELI® (pegcetacoplan), a complement inhibitor, for the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) to reduce proteinuria.","length":411,"tagName":"p"},{"type":"text","content":"EMPAVELI® is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases.","length":207,"tagName":"p"},{"type":"text","content":"“Health Canada’s approval of EMPAVELI® for the treatment of C3G or primary IC-MPGN marks an important milestone for patients and families in Canada living with these rare and serious kidney diseases,” said Bob McLay, VP, General Manager of Sobi Canada. “For many in the kidney community, there have been limited treatment options and a long wait for new therapeutic advances. This approval brings renewed hope to patients and caregivers by providing a treatment option that stabilizes kidney function, addresses the underlying disease process and is supported by strong clinical evidence. We are proud to bring this important therapy to patients in Canada and remain committed to supporting the community as access expands.”","length":724,"tagName":"p"},{"type":"...